StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ANGOBullishEarningsnews
High materiality8/10

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 12:18 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong Q4 results exceeding estimates may drive investor confidence, similar to past performance spikes.

AI summary

What happened, with direct paths to the underlying reporting

ANGO's Q4 loss was 3 cents per share, beating expectations. Sales reached $80.2 million, exceeding consensus estimates by 8.7%. Med Tech sales rose 22% year-over-year, primarily driven by Auryon. 2026 revenue guidance is $305-$310 million, slightly exceeding consensus. Stock increased 5.3% to $10.14 following positive earnings report.

  • ANGO's Q4 loss was 3 cents per share, beating expectations.
  • Sales reached $80.2 million, exceeding consensus estimates by 8.7%.
  • Med Tech sales rose 22% year-over-year, primarily driven by Auryon.
  • 2026 revenue guidance is $305-$310 million, slightly exceeding consensus.
  • Stock increased 5.3% to $10.14 following positive earnings report.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event